Eylea® Injection for Wet Age-Related Macular Degeneration

What Eylea Is and How It Works

Eylea® is a vascular endothelial growth factor (VEGF) inhibitor used for retinal diseases that damage central vision. The medicine is given as an intravitreal treatment by an eye specialist. Many patients value cross-border access with US delivery from Canada, especially when paying without insurance.

CanadianInsulin.com is a prescription referral platform. We verify prescriptions with your prescriber when required, and licensed Canadian pharmacies dispense your order.

This anti-VEGF therapy blocks VEGF, a signal that promotes abnormal blood vessels and leakage in the retina. By reducing VEGF activity, it can help limit fluid accumulation and neovascular changes. The result may be stabilization of vision or improvement in some people under a specialist’s care. Talk with your retina clinician about expected outcomes and monitoring.

The eylea injection is administered only in a clinical setting under sterile conditions. Your provider will evaluate your eye before and after each dose and track your response over time.

Who It’s For

This treatment is indicated for neovascular (wet) age-related macular degeneration. It is also approved for diabetic macular edema and for diabetic retinopathy. For macular edema following retinal vein occlusion, your retina specialist may recommend this option based on exam findings. In select regions, aflibercept is additionally used for retinopathy of prematurity under specific pediatric protocols.

Patients with active ocular infection or severe intraocular inflammation should not receive injections until the condition has cleared. Tell your clinician about recent eye surgeries or procedures, glaucoma history, or any sensitivity to components of aflibercept. Learn more about the condition landscape under Wet AMD, Diabetic Macular Edema, Diabetic Retinopathy, and Retinal Vein Occlusion.

Dosage and Usage

Specialists follow labeled regimens. Initial dosing typically starts with a series of monthly injections. After the loading phase, intervals may extend based on clinical response and imaging. Your prescriber may use a fixed schedule, or a treat-and-extend approach as supported by guidelines and the product label.

Typical patterns differ by condition. For wet AMD and diabetic macular edema, many clinicians begin with monthly injections, then move to every other month or longer if the retina remains dry. For vein occlusion, monthly dosing is often continued until stability is observed. Always follow your clinician’s plan; individual schedules may vary.

Discuss eylea dosing with your retina specialist before starting therapy. If you have questions about administration steps, ask the clinic to explain the visit workflow, numbing, antiseptic preparation, and brief vision checks after the injection.

Strengths and Forms

This therapy is available in a standard presentation and a higher-dose presentation referred to as HD. The medicine is supplied as single-use units prepared for intravitreal administration. Availability can include single-use vials and ready-to-use prefilled options, depending on the strength and market.

Your clinic may order a vial or a device with a pre-attached syringe. Ask your provider which configuration they plan to use on the day of treatment. The eylea prefilled syringe may reduce preparation steps in eligible cases. Availability can vary by region and by strength; stock may differ over time.

Missed Dose and Timing

If a scheduled clinic injection is missed or delayed, contact your eye care team to reschedule as soon as practical. The prescriber will decide the next visit date and dosing interval. Avoid self-adjusting appointment timing without speaking to your retina specialist.

Storage and Travel Basics

This product is typically stored by clinics under refrigeration in its original carton and protected from light. Do not freeze. If you are directed to carry it to an appointment, keep it in the labeled carton, follow any cooling instructions from the pharmacy, and avoid temperature extremes.

Do not shake the unit. Keep all medications away from children and pets. When traveling to your injection visit, allow extra time for check-in and bring photo ID and your prescription details. If you have questions about transport, ask your pharmacy or clinic for specific handling steps.

Pen Handling and Sharps Disposal

This medicine is administered by a trained clinician as an intravitreal procedure. Patients should not self-inject. The aflibercept injection unit is single-use; it must not be re-used or shared. Clinics dispose of used supplies in a sharps container following local regulations.

Benefits

Anti-VEGF therapy directly targets a key driver of wet retinal disease. Many patients benefit from clinician-guided dosing schedules and imaging-based adjustments. Extended intervals may be possible for some individuals after the first few treatments.

The treatment is performed in-office with topical anesthetic and antiseptic preparation. Your care team monitors for comfort during the short procedure. Regular follow-up visits help assess retinal fluid and visual function.

Side Effects and Safety

• Eye pain or discomfort, usually mild and short-lived
• Conjunctival redness or small surface hemorrhages
• Floaters or the sensation of a spot in vision
• Temporary rise in intraocular pressure after injection
• Foreign body sensation, tearing, or irritation

Serious but less common risks include intraocular infection (endophthalmitis), retinal detachment, cataract progression, significant inflammation, and sustained elevated intraocular pressure. Rare arterial thromboembolic events have been reported with anti-VEGF agents. Seek immediate care if you experience sudden pain, worsening redness, light sensitivity, a marked drop in vision, or new flashes and floaters.

Tell your clinician about all medical conditions, including cardiovascular history and pregnancy plans. This medicine is not for use if you have an active eye infection or severe ocular inflammation. Your prescriber will provide post-injection guidance and emergency contact procedures.

Drug Interactions and Cautions

Because the treatment acts locally inside the eye, systemic drug interactions are uncommon. However, your clinician should know all medications and supplements you use, including antiplatelet or anticoagulant therapies. Report recent or planned eye surgeries, glaucoma treatments, or any hypersensitivity reactions to prior injections.

If you have diabetes, your overall eye health plan may also include control of blood glucose and blood pressure. For background education on protecting vision, see our article How Diabetes Affects Eyes and this overview of Diabetic Eye Disease.

What to Expect Over Time

Early treatment focuses on drying retinal fluid and controlling leakage. Some people notice vision stabilization first, followed by gradual improvements, while others primarily maintain their current level. Response is assessed with dilated exam and optical coherence tomography.

As the retina stabilizes, your clinician may consider extending intervals. Keep all follow-up visits and promptly report any new or worsening symptoms between appointments. Consistent adherence helps the care team tailor the plan to your eye’s needs.

Compare With Alternatives

Retina specialists may discuss other anti-VEGF options if needed. Two common alternatives include Lucentis Vial and Beovu Pre-Filled Syringe. Choice depends on medical history, exam findings, and your prescriber’s judgment.

Pricing and Access

We offer Canadian-sourced options with US shipping from Canada. Check today’s eylea price on the product page to review current availability. If you pay a cash price, you can compare options with your clinician or clinic buyer. Out-of-pocket cost varies by insurance, clinic billing, and the selected presentation.

Looking for savings opportunities? See current Promotions and discuss multi-visit planning with your provider or clinic. You can use our site to review supply options and place orders through encrypted checkout.

Availability and Substitutions

Supply can vary by clinic demand and manufacturer distribution. If a specific presentation is unavailable, your prescriber may recommend an appropriate alternative or adjust timing based on your clinical needs. We do not provide medical advice about substitutions; follow your clinician’s plan.

Patient Suitability and Cost-Saving Tips

This therapy may suit adults with wet AMD, diabetic eye disease, or vein-occlusion–related edema after evaluation by a retina specialist. It is not suitable for those with active ocular infection or significant intraocular inflammation at the time of injection. Discuss pregnancy and breastfeeding considerations with your clinician.

Cost-conscious tips include coordinating injections on a consistent schedule, aligning clinic visits with prescription refills, and asking about clinic-administered billing pathways. If your clinician advises it, arranging multiple units for clinic stock can reduce last-minute ordering and missed appointments. Set reminders for follow-up visits so treatment stays on track.

Questions to Ask Your Clinician

• Diagnosis and goals: what the injection aims to achieve
• Visit schedule: loading plan and possible interval extension
• Imaging plan: how OCT guides decisions
• Safety checks: signs that require same-day contact
• Logistics: clinic handling, transport, and storage steps
• Costs: expected charges and any financial counseling

Authoritative Sources

For full prescribing information and safety, see the manufacturer’s label on Regeneron’s website, which provides indications and administration details. Regeneron EYLEA Prescribing Information.

For official US labeling with additional sections on warnings and dosage, review the FDA DailyMed entry. FDA DailyMed: Aflibercept Injection.

For Canadian product details and regulatory status, consult Health Canada’s Drug Product Database. Health Canada DPD: Eylea.

Order from CanadianInsulin for prompt, express, cold-chain shipping and careful handling to your clinic or appointment location. Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice.